Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 49

1.

miR-125b Upregulates miR-34a and Sequentially Activates Stress Adaption and Cell Death Mechanisms in Multiple Myeloma.

Misso G, Zarone MR, Lombardi A, Grimaldi A, Cossu AM, Ferri C, Russo M, Vuoso DC, Luce A, Kawasaki H, Di Martino MT, Virgilio A, Festa A, Galeone A, De Rosa G, Irace C, Donadelli M, Necas A, Amler E, Tagliaferri P, Tassone P, Caraglia M.

Mol Ther Nucleic Acids. 2019 Mar 13;16:391-406. doi: 10.1016/j.omtn.2019.02.023. [Epub ahead of print]

2.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.

Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C.

J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.

3.

Cell communication and signaling: how to turn bad language into positive one.

Chiodoni C, Di Martino MT, Zazzeroni F, Caraglia M, Donadelli M, Meschini S, Leonetti C, Scotlandi K.

J Exp Clin Cancer Res. 2019 Mar 13;38(1):128. doi: 10.1186/s13046-019-1122-2.

4.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.

Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P.

Clin Pharmacol Ther. 2019 Feb 10. doi: 10.1002/cpt.1391. [Epub ahead of print]

PMID:
30739312
5.

Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.

Rigiracciolo DC, Santolla MF, Lappano R, Vivacqua A, Cirillo F, Galli GR, Talia M, Muglia L, Pellegrino M, Nohata N, Di Martino MT, Maggiolini M.

J Exp Clin Cancer Res. 2019 Feb 6;38(1):58. doi: 10.1186/s13046-019-1056-8.

6.

Pharmacogenomic Profiling of ADME Gene Variants: Current Challenges and Validation Perspectives.

Arbitrio M, Martino MTD, Scionti F, Barbieri V, Pensabene L, Tagliaferri P.

High Throughput. 2018 Dec 18;7(4). pii: E40. doi: 10.3390/ht7040040. Review.

7.

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology.

Gallo Cantafio ME, Grillone K, Caracciolo D, Scionti F, Arbitrio M, Barbieri V, Pensabene L, Guzzi PH, Di Martino MT.

High Throughput. 2018 Oct 26;7(4). pii: E33. doi: 10.3390/ht7040033. Review.

8.

The Cytoscan HD Array in the Diagnosis of Neurodevelopmental Disorders.

Scionti F, Di Martino MT, Pensabene L, Bruni V, Concolino D.

High Throughput. 2018 Sep 14;7(3). pii: E28. doi: 10.3390/ht7030028. Review.

9.

The potential role of miRNAs in multiple myeloma therapy.

Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P.

Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Review.

PMID:
30148649
10.

miR-22 suppresses DNA ligase III addiction in multiple myeloma.

Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P.

Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17.

11.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11.

12.

miR-221 stimulates breast cancer cells and cancer-associated fibroblasts (CAFs) through selective interference with the A20/c-Rel/CTGF signaling.

Santolla MF, Lappano R, Cirillo F, Rigiracciolo DC, Sebastiani A, Abonante S, Tassone P, Tagliaferri P, Di Martino MT, Maggiolini M, Vivacqua A.

J Exp Clin Cancer Res. 2018 May 2;37(1):94. doi: 10.1186/s13046-018-0767-6.

13.

Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.

Di Martino MT, Zazzeroni F, Donadelli M, Chiodoni C, Caraglia M, Scotlandi K, Meschini S, Leonetti C.

J Exp Clin Cancer Res. 2018 Mar 5;37(1):48. doi: 10.1186/s13046-018-0710-x. No abstract available.

14.

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

Scionti F, Di Martino MT, Sestito S, Nicoletti A, Falvo F, Roppa K, Arbitrio M, Guzzi PH, Agapito G, Pisani A, Riccio E, Concolino D, Pensabene L.

Oncotarget. 2017 Nov 18;8(64):107558-107564. doi: 10.18632/oncotarget.22505. eCollection 2017 Dec 8.

15.

Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.

Zarone MR, Misso G, Grimaldi A, Zappavigna S, Russo M, Amler E, Di Martino MT, Amodio N, Tagliaferri P, Tassone P, Caraglia M.

Sci Rep. 2017 Dec 20;7(1):17949. doi: 10.1038/s41598-017-18186-0.

16.

Genetic variants associated with gastrointestinal symptoms in Fabry disease.

Di Martino MT, Scionti F, Sestito S, Nicoletti A, Arbitrio M, Hiram Guzzi P, Talarico V, Altomare F, Sanseviero MT, Agapito G, Pisani A, Riccio E, Borrelli O, Concolino D, Pensabene L.

Oncotarget. 2016 Dec 27;7(52):85895-85904. doi: 10.18632/oncotarget.13135.

17.

OSAnalyzer: A Bioinformatics Tool for the Analysis of Gene Polymorphisms Enriched with Clinical Outcomes.

Agapito G, Botta C, Guzzi PH, Arbitrio M, Di Martino MT, Tassone P, Tagliaferri P, Cannataro M.

Microarrays (Basel). 2016 Sep 23;5(4). pii: E24. doi: 10.3390/microarrays5040024.

18.

Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human Primates.

Gallo Cantafio ME, Nielsen BS, Mignogna C, Arbitrio M, Botta C, Frandsen NM, Rolfo C, Tagliaferri P, Tassone P, Di Martino MT.

Mol Ther Nucleic Acids. 2016 Jun 21;5(6). doi: 10.1038/mtna.2016.36.

19.

DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

Arbitrio M, Di Martino MT, Scionti F, Agapito G, Guzzi PH, Cannataro M, Tassone P, Tagliaferri P.

Oncotarget. 2016 Aug 16;7(33):54028-54050. doi: 10.18632/oncotarget.9927. Review.

20.

Non Coding RNAs: A New Avenue for the Self-Tailoring of Blood Cancer Treatment.

Misso G, Zarone MR, Grimaldi A, Di Martino MT, Lombardi A, Kawasaki H, Stiuso P, Tassone P, Tagliaferri P, Caraglia M.

Curr Drug Targets. 2017;18(1):35-55. Review.

PMID:
27280795

Supplemental Content

Loading ...
Support Center